Background: Sentinel lymph node (SLN) biopsy remains a cornerstone in the management of breast cancer, as it provides an accurate staging of the disease while minimizing the morbidity associated with complete axillary lymph node dissection. Advances in SLN detection have been very important in refining surgical techniques and improving patient outcomes. The purpose of the present study is to compare the effectiveness of radiocolloids, blue dyes, and fluorescent tracers in detecting the sentinel lymph node in breast cancer. Materials and Methods: Specifically, we analyzed the detection rate, accuracy, and safety profile of the techniques to outline the most reliable and clinically available. A comprehensive review was conducted, searching key databases, including PubMed, Scopus, and Web of Science, for studies published between 2010 and 2024. The review focused on studies that compared the performance of radiocolloids, blue dyes, and fluorescent tracers in the detection of sentinel lymph nodes in breast cancer patients. A total of 54 studies were included based on specific inclusion criteria. Results: Radiocolloids showed high detection rates in studies. Blue dyes have comparable results, but a small percentage of allergic reactions has been observed. Fluorescent tracers such as indocyanine green have improved visualization and accuracy, but their use requires specialized equipment and expertise. Combining radiocolloids with blue dyes or fluorescent tracers has improved detection rates in several studies. Cost and accessibility challenges have also been pointed out, particularly in low-resource settings. Conclusions: Radiocolloids have attained the status of gold standard in the detection of SLNs in breast cancer for their reliability and accuracy. While combined use with other tracers, like blue dyes or fluorescent agents, enhances overall detection performance, making it more holistic. As expected, further innovation and effort are required to improve accessibility and optimize the technique of sentinel lymph node biopsy worldwide.
References
[1]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemalet, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[2]
Sha, R., Kong, X.M., Li, X.Y. and Wang, Y.B. (2024) Global Burden of Breast Cancer and Attributable Risk Factors in 204 Countries and Territories, from 1990 to 2021: Results from the Global Burden of Disease Study 2021. Biomarker Research, 12, Article No. 87. https://doi.org/10.1186/s40364-024-00631-8
[3]
World Health Organization (2024) Breast Cancer, Accesses on October 21, 2024. https://www.who.int/news-room/fact-sheets/detail/breast-cancer
[4]
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R. and Stanisławek, A. (2021) Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. Cancers (Basel), 13, Article 4287. https://doi.org/10.3390/cancers13174287
[5]
Hercules, S.M., Alnajar, M., Chen, C., Mladjenovic, S.M., Shipeolu, B.A., Perkovic, O., Pond, G.R., Mbuagbaw, L., Blenman, K.R. and Daniel, J.M. (2022) Triple-Negative Breast Cancer Prevalence in Africa: A Systematic Review and Meta-Analysis. BMJ Open, 12, e055735. https://doi.org/10.1136/bmjopen-2021-055735
[6]
Barrios, C.H. (2022) Global Challenges in Breast Cancer Detection and Treatment. Breast, 62, S3-S6. https://doi.org/10.1016/j.breast.2022.02.003
[7]
Zhu, J.W., Charkhchi, P., Adekunte, S. and Akbari, M.R. (2023) What Is Known about Breast Cancer in Young Women? Cancers (Basel), 15, Article 1917. https://doi.org/10.3390/cancers15061917
[8]
Kuchenbaecker, K.B., Hopper, J.L., Barnes, D.R., Phillips, K.A., Mooij, T.M., Roos-Blom, M.J., Jervis, S., van Leeuwen, F.E., Milne, R.L., Andrieu, N., et al. (2017) Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA, 317, 2402-2416. https://doi.org/10.1001/jama.2017.7112
[9]
Adrees, U., Shoaib, N., Gull, S., Imran, H., Saleem, F., Tahir, A. and Khan, Z. (2024) Expression of Hormone Receptors and Human Epidermal Growth Factor2/Neu in Female Breast Cancer Patients. Kuwait Journal of Science, 51, Article 100270. https://doi.org/10.1016/j.kjs.2024.100270
[10]
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, A., Pawlicki, M., et al. (2011) Breast Cancer International Research Group. Adjuvant Trastuzumab in HER2-Positive Breast Cancer. The New England Journal of Medicine, 365, 1273-1283. https://doi.org/10.1056/NEJMoa0910383
[11]
Jayasekera, J., Zhao, A., Schechter, C., Lowry, K., Yeh, J.M., Schwartz, M.D., O’Neill, S., Wernli, K.J., Stout, N., Mandelblatt, J., Kurian, A.W. and Isaacs, C. (2023) Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer. Journal of Clinical Oncology, 41, 859-870. https://doi.org/10.1200/JCO.22.01342
[12]
Soliman, N.A. and Yussif, S.M. (2016) Ki-67 as a Prognostic Marker According to Breast Cancer Molecular Subtype. Cancer Biology & Medicine, 13, 496-504. https://doi.org/10.20892/j.issn.2095-3941.2016.0066
[13]
Tinterri, C., Barbieri, E., Sagona, A., Bottini, A., Canavese, G., Gentile, D. (2024) De-Escalation Surgery in cT3-4 Breast Cancer Patients after Neoadjuvant Therapy: Predictors of Breast Conservation and Comparison of Long-Term Oncological Outcomes with Mastectomy. Cancers, 16, Article 1169. https://doi.org/10.3390/cancers16061169
[14]
Goutsouliak, K., Veeraraghavan, J., Sethunath, V., De Angelis, C., Osborne, C.K., Rimawi, M.F. and Schiff, R. (2020) Towards Personalized Treatment for Early Stage HER2-Positive Breast Cancer. Nature Reviews Clinical Oncology, 17, 233-250. https://doi.org/10.1038/s41571-019-0299-9
[15]
Gentile, D. and Tinterri, C. (2024) Sentinel Lymph Node Biopsy versus Axillary Lymph Node Dissection in Breast Cancer Patients Undergoing Mastectomy. Minerva Surgical, 79, 545-557. https://doi.org/10.23736/S2724-5691.24.10485-6
[16]
Garcia-Tejedor, A., Ortega-Exposito, C., Salinas, S., Luzardo-González, A., Falo, C., Martinez-Pérez, E., Pérez-Montero, H., Soler-Monsó, M.T., Bajen, M.T., Benitez, A., et al. (2023) Axillary Lymph Node Dissection versus Radiotherapy in Breast Cancer with Positive Sentinel Nodes after Neoadjuvant Therapy (ADARNAT Trial). Frontiers in Oncology, 13, Article 1184021. https://doi.org/10.3389/fonc.2023.1184021
[17]
Anuszkiewicz, K., Jankau, J. and Kur, M. (2023) What Do We Know about Treating Breast-Cancer-Related Lymphedema? Review of the Current Knowledge about Therapeutic Options. Breast Cancer, 30, 187-199. https://doi.org/10.1007/s12282-022-01428-z
[18]
Mathelin, C. and Lodi, M. (2021) Narrative Review of Sentinel Lymph Node Biopsy in Breast Cancer: A Technique in Constant Evolution with Still Numerous Unresolved Questions. Chinese Clinical Oncology, 10, Article 20. https://doi.org/10.21037/cco-20-207
[19]
Cimino-Mathews, A. (2021) Novel Uses of Immunohistochemistry in Breast Pathology: Interpretation and Pitfalls, Modern Pathology, 34, 62-77. https://doi.org/10.1038/s41379-020-00697-3
[20]
Giuliano, A.E., Ballman, K.V., McCall, L., Beitsch, P.D., Brennan, M.B., Kelemen, P.R., Ollila, D.W., Hansen, N.M., Whitworth, P.W., Blumencranz, P.W., et al. (2017) Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival among Women with Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 565 (Alliance) Randomized Clinical Trial. JAMA, 318, 918-926. https://doi.org/10.1001/jama.2017.11470
[21]
Galimberti, V., Cole, B.F., Zurrida, S., Viale, G., Luini, A., Veronesi, P., Baratella, P., Chifu, C., Sargenti, M., Intra, M., et al. (2013) Axillary Dissection versus No Axillary Dissection in Patients with Sentinel-Node Micrometastases (IBCSG 23-01): A Phase 3 Randomised Controlled Trial. The Lancet Oncology, 14, 297-305. https://doi.org/10.1016/S1470-2045(13)70035-4
[22]
Jagsi, R., Chadha, M., Moni, J., Ballman, K., Laurie, F., Buchholz, T.A., Giuliano, A. and Haffty, B.G. (2014) Radiation Field Design in the ACOSOG Z0011 (Alliance) Trial. Journal of Clinical Oncology, 32, 3600-3606. https://doi.org/10.1200/JCO.2014.56.5838
[23]
Gentilini, O. and Veronesi, U. (2012) Sentinel Lymph Node Biopsy in Abandoning Early Breast Cancer? A New Trial in Progress at the European Institute of Oncology Milan. Breast, 21, 678-681. https://doi.org/10.1016/j.breast.2012.06.013
[24]
Berrocal, J., Saperstein, L., Grube, B., Horowitz, N.R., Chagpar, A.B., Killelea, B.K. and Lannin, D.R. (2017) Intraoperative Injection of Technetium-99m Sulfur Colloid for Sentinel Lymph Node Biopsy in Breast Cancer Patients: A Single Institution Experience. Surgery Research and Practice, Article 5924802. https://doi.org/10.1155/2017/5924802
[25]
White, K.P., Sinagra, D., Dip, F., Rosenthal, R.J., Mueller, E.A., Lo Menzo, E. and Rancati, A. (2024) Indocyanine Green Fluorescence versus Blue Dye, Technetium-99M, and the Dual-Marker Combination of Technetium-99M + Blue Dye for Sentinel Lymph Node Detection in Early Breast Cancer-Meta-Analysis Including Consistency Analysis. Surgery, 175, 963-973. https://doi.org/10.1016/j.surg.2023.10.021
[26]
Krag, D.N., Weaver, D.L., Alex, J.C. and Fairbank, J.T. (1993) Surgical Resection and Radiolocalization of the Sentinel Lymph Node in Breast Cancer Using a Gamma Probe. Surgical Oncology, 2, 335-340. https://doi.org/10.1016/0960-7404(93)90064-6
[27]
Zhang, Y., Wang, P., Jing, H. and Li, F. (2024) 99mTc-ABH2 SPECT/CT for Imaging HER2 Expression in Breast Cancer: A Preliminary Study. Journal of Nuclear Medicine, 65, Article 241887. https://jnm.snmjournals.org/content/65/supplement_2/241887
[28]
Boschi, A., Uccelli, L. and Martini, P. (2019) A Picture of Modern Tc-99m Radiopharmaceuticals: Production, Chemistry, and Applications in Molecular Imaging. Applied Sciences, 9, Article 2526. https://doi.org/10.3390/app9122526
[29]
White, V., Harvey, J.R., Griffith, C.D., Youssef, M. and Carr, M. (2011) Sentinel Lymph Node Biopsy in Early Breast Cancer Surgery-Working with the Risks of Vital Blue Dye to Reap the Benefits. European Journal of Surgical Oncology, 37, 101-108. https://doi.org/10.1016/j.ejso.2010.12.007
[30]
Dai, Z.Y., Shen, C., Mi, X.Q. and Pu, Q. (2023) The Primary Application of Indocyanine Green Fluorescence Imaging in Surgical Oncology. Frontiers in Surgery, 10, Article 1077492. https://doi.org/10.3389/fsurg.2023.1077492
[31]
Akrida, I., Michalopoulos, N.V., Lagadinou, M., Papadoliopoulou, M., Maroulis, I. and Mulita, F. (2023) An Updated Review on the Emerging Role of Indocyanine Green (ICG) as a Sentinel Lymph Node Tracer in Breast Cancer. Cancers, 15, Article 5755. https://doi.org/10.3390/cancers15245755
[32]
Kwong, A., Cheung, B.H.H. and Man, V.C.M. (2023) Sentinel Lymph Node Mapping in Breast Cancer: Evaluating the Dual-Tracer Method with Indocyanine Green and Radioisotope. Annals of Oncology, 34, S314. https://doi.org/10.1016/j.annonc.2023.09.522
[33]
Man, V., Cheung, M., Lo, C., Poy Wing Lam, T. and Kwong, A. (2023) Superparamagnetic Iron Oxide Sentinel Lymph Node Biopsy in Early Breast Cancer: An Analysis of Artefacts on Post-Operative Breast Imaging. Annals of Breast Surgery, 7, 1-9. https://doi.org/10.21037/abs-21-110
[34]
Liu, P., Tan, J., Song, Y., Huang, K., Zhang, Q. and Xie, H. (2022) The Application of Magnetic Nanoparticles for Sentinel Lymph Node Detection in Clinically Node-Negative Breast Cancer Patients: A Systemic Review and Meta-Analysis. Cancers (Basel), 14, Article 5034. https://doi.org/10.3390/cancers14205034
[35]
Bai, S., Gai, L., Zhang, Q., Kang, Y., Liu, Z., He, Y., Liu, W., Jiang, T., Du, Z., Du, S., Gao, S., Zhang, M. and Li, T. (2024) Development of a Human-Size Magnetic Particle Imaging Device for Sentinel Lymph Node Biopsy of Breast Cancer. Frontiers in Bioengineering and Biotechnology, 12, Article 1327521. https://doi.org/10.3389/fbioe.2024.1327521
[36]
Wang, T., Xu, Y., Shao, W. and Wang, C. (2022) Sentinel Lymph Node Mapping: Current Applications and Future Perspectives in Gynecology Malignant Tumors. Frontiers in Medicine, 9, Article 922585. https://doi.org/10.3389/fmed.2022.922585
[37]
Abidi, H. and Bold, R.J. (2023) Assessing the Sentimag System for Guiding Sentinel Node Biopsies in Patients with Breast Cancer. Expert Review of Medical Devices, 21, 1-9. https://doi.org/10.1080/17434440.2023.2284790
[38]
Yang, J., Xu, L., Liu, P., Du, Z., Chen, J., Liang, F., Long, Q., Zhang, D., Zeng, H. and Lv, Q. (2020) Accuracy of Sentinel Lymph Node Biopsy in Breast Cancer: Pitfalls in the Application of Single Tracers. Cancer Management and Research, 12, 3045-3051. https://doi.org/10.2147/CMAR.S244806
[39]
Trusova, V., Karnaukhov, I., Zelinsky, A., Borts, B., Ushakov, I., Sidenko, L. and Gorbenko, G. (2024) Radiolabeling of Bionanomaterials with Technetium 99 m: Current State and Future Prospects. Nanomedicine (London, England), 19, 1569-1580. https://doi.org/10.1080/17435889.2024.2368454
